RECENT FUNDING ROUNDS


Country Profile Funding round Value Date
Neurelis Inc Neuroscience company. Series D USD 114,000,000
Maridose LLC Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs. Pre Seed USD 150,000
Gilgamesh Pharmaceuticals Inc Novel psychedelic-Inspired therapeutics for treating mental illness. Seed
3-V Biosciences Inc Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. Series B USD 30,000,000
Vyome Biosciences Pvt Ltd Developer of medicines for treating skin diseases caused by resistant microbes. Series C USD 14,000,000
Arcis Biotechnology Holdings Ltd N/A GBP 2,500,000
FunkSac LLC Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. N/A
23andMe Inc DNA testing and genome sequencing firm. Series E USD 79,100,000
3SBio Inc IPO HKD 5,510,000,000
Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Acquisition USD 3,500,000,000
Omega Pharma Belgium NV Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide. Acquisition USD 4,500,000,000
InterMune Inc Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Acquisition USD 8,300,000,000
23andMe Inc DNA testing and genome sequencing firm. Grant USD 1,400,000
ViroPharma Inc Provider of life-saving medicines for life-threatening diseases. Acquisition USD 495,000,000
Merck & Co Acquisition USD 14,200,000,000
Arecor Ltd Developer of technology that is used in the formulation of biopharmaceuticals. N/A
ViroPharma Inc Provider of life-saving medicines for life-threatening diseases. Acquisition USD 4,200,000,000
Zosano Pharma Inc Debt USD 3,030,000
3-V Biosciences Inc Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. Series C USD 20,000,000
Warner Chilcott Corp Acquisition USD 8,500,000,000

MOST ACTIVE INVESTORS

New Enterprise Associates Inc US 97
Alta Partners LP US 58
Domain Associates LLC US 49
Healthcare Ventures LLC US 48
Venrock Associates US 37
Frazier Healthcare Ventures US 35
OrbiMed Advisors LLC US 34
Novartis Services Inc US 31
Hercules Technology Growth Capital Inc US 28
MPM Capital US 27
Sanderling Ventures US 24
Vivo Ventures LLC US 24
Essex Woodlands Health Ventures Inc US 23
Kleiner Perkins Caufield & Byers LLC US 23
ARCH Venture Partners LP US 22
Versant Ventures Management LLC US 22
CHL Medical Partners US 22
InterWest Partners US 21
Pappas Ventures US 20
Bay City Capital LLC US 20
Fidelity Biosciences Group US 20
Forward Ventures Services LLC US 20
MPM Asset Management LLC US 20
Polaris Venture Partners Inc US 19
Delphi Ventures Inc US 19
Quaker BioVentures Inc US 18
BioAdvance - Biotechnology Greenhouse Corporation of Southeastern Pennsylvania US 18
Sutter Hill Ventures LP US 18
Flagship Ventures US 18
Johnson & Johnson Innovation LLC US 18
Thomas McNerney & Partners LLC US 17
ProQuest Investments US 17
Novartis Venture Funds CH 17
TPG Capital LP US 16
TPG Growth LLC US 16
NGN Capital LLC US 16
Ben Franklin Technology Partners of Southeastern Pennsylvania US 16
Clarus Ventures LLC US 16
HBM BioVentures AG CH 16
Sofinnova Ventures Inc US 16
Third Rock Ventures LLC US 16
Canaan Partners US 16
SR One Ltd US 16
One Liberty Ventures US 16
Montreux Equity Partners US 16
Prospect Venture Partners US 16
New Leaf Venture Partners US 15
Lilly Ventures US 15
Red Abbey Venture Partners LLC US 15
Astellas Venture Management LLC US 15

BEST FUNDED STARTUPS


Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.

Provider of life-saving medicines for life-threatening diseases.

Belgian pharmaceutical company manufacturing and marketing a wide range of over-the-counter products in 35 countries worldwide.

A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

DNA testing and genome sequencing firm.

Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.

Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.

Personalized medicine company specializing in pharmacogenetics

Developer of prostate cancer drugs

Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.

Developer of small molecule therapeutics for the treatment of inflammatory disease

Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases